Summary
Acadia’s Daybue, treating Rett syndrome, shows strong market entry with sales of $90.1 million in the first six months, indicating significant market potential.
Acadia's financials are robust with rising net product sales and a strong current ratio, but increasing operating expenses and net losses.Market confidence in Acadia is moderate, with high institutional ownership and insider buying, but mixed stock momentum.
Recommend "Buy" for Acadia due to Daybue's market potential, despite the need for careful financial management and market monitoring.
Neuren Media and Analyst Coverage, page-535
-
- There are more pages in this discussion • 730 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |